HRMY P/B: current value, 10-year range and year-by-year history
Cash & Leverage
HRMY's p/b is lower than 83% of the last 10 years.
P/B History
HRMY P/B by year
Yearly range of HRMY’s p/b from 2020 to 2026. Over the full period it ranged from -56.6 to 32.5, averaging 6.9.
| Year | Low | Average | High | Year-end |
|---|---|---|---|---|
| 2026 | 1.8 | 2.2 | 2.6 | 2.3 |
| 2025 | 1.8 | 2.7 | 3.6 | 2.5 |
| 2024 | 3.0 | 3.6 | 4.4 | 3.0 |
| 2023 | 2.4 | 4.9 | 8.2 | 4.1 |
| 2022 | 7.9 | 11.9 | 16.5 | 9.8 |
| 2021 | 11.9 | 16.7 | 23.6 | 13.8 |
| 2020 | -56.6 | 3.2 | 32.5 | 21.2 |
Get notified when HRMY P/B crosses a threshold
Free — one alert setup, notifications by push, Telegram, or Discord.
How much the market pays relative to the company's accounting net worth (assets minus liabilities). P/B < 1 means the market values the company below what the books say it owns.
Price / Book Value Per ShareMost useful for asset-heavy businesses: banks, insurers, REITs. A P/B near its historical low suggests the market is paying unusually little for the net assets.
- Goodwill and intangibles from acquisitions can inflate book value significantly — some analysts prefer tangible book value.
- Low P/B in technology or software companies is usually irrelevant: their value is in IP and people, not balance sheet assets.
Is HRMY P/B High or Low Right Now?
Harmony Biosciences Holdings, Inc.'s P/B is currently 2.3, which is historically cheap relative to its 10-year historical range. The 10-year median P/B for HRMY is approximately 4.2. See all HRMY valuation metrics →
Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.